Observational study seeking markers to identify autism subgroups
Studies people with autism to find markers that may predict medication response.
Plain-language title generated from the registry record
Registry title: International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
Key facts
- Where
- Alicante, Barcelona, Madrid, Majadahonda, San Sebastián, and Vigo, SpainSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 65 years old?
Source: NCT05590715, who can take part
Where in Spain
- Hospital General Universitario Dr. BalmisAlicante, SpainTaking people
- Hospital Clinic of BarcelonaBarcelona, SpainTaking people
- Hospital Infantil Universitario Nino Jesus (HIUNJS)Madrid, SpainTaking people
- Hospital Universitario Infanta LeonorMadrid, SpainTaking people
- Hospital Universitario Puerta de Hierro - MajadahondaMajadahonda, SpainNo longer taking part
- Policlina GipuzkoaSan Sebastián, SpainNo longer taking part
- Hospital Alvaro CunqueiroVigo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stalicla SA
- Trial code
- NCT05590715
- Record updated
- 27 April 2026
- Original description
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medicationRead full original descriptionShow less
International, Multicentric, Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication
Inclusion: Participants previously diagnosed with ASD (DSM-5); Available well-documented health records within the first 2 years of life; Participants must have a parent or reliable caregiver who agrees to provide information about the participant; Participants willing and consenting or assenting to participate.
Exclusion: Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or clinically significant illness without fever (as judged by the investigator), within 10 days before any study assessment; If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study.